Humana Inc. ($HUM) Stock Forecast: Up 5.2% Today

What is Humana Inc.?

Humana Inc. (HUM) is a leading health insurance company in the United States, offering a wide range of insurance products and health and wellness services. The company is known for its innovative healthcare solutions and strong market presence in the industry.

Why is Humana Inc. going up?

HUM stock is up 5.2% on Apr 28, 2026 16:05

• Humana (HUM) experienced a strong bullish movement today, with shares rising by 3.9%.
• The positive market movement can be attributed to the overall positive sentiment in the health insurance sector, as investors anticipate the company's Q1 earnings report.
• Analysts and investors are showing confidence in Humana's future performance, as indicated by the significant undervaluation of the stock according to GuruFocus' GF Value estimate.
• The upcoming earnings report and expectations for strong revenue growth are likely driving the bullish momentum in Humana's stock price.

HUM Price Chart

HUM Technical Analysis

HUM News

Full Transcript: Centene Q1 2026 Earnings Call

Centene (NYSE: CNC) reported strong Q1 2026 adjusted diluted EPS of $3.37, surpassing expectations and leading to an increased full-year EPS guidance of over $3.40. The company saw excellent performance in its Medicaid, Medicare, and Marketplace segments, with strategic initiatives in trend management, fraud prevention, and value-based care driving positive results. Centene also announced leadership structure changes and highlighted progress in balance sheet improvement through debt reduction.

https://www.benzinga.com/insights/news/26/04/52096778/full-transcript-centene-q1-2026-earnings-call

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics, through its subsidiary CNSide Diagnostics, LLC, has secured coverage from Blue Shield of California for its CNSide Cerebrospinal Fluid Assay. This agreement expands access for patients with metastatic central nervous system cancers by adding 6 million covered lives, bringing the total to 81 million, and aims to reduce reimbursement barriers for the CNSide test. The company is advancing towards its 2026 goal of 150 million covered lives, enhancing the commercial momentum for its diagnostic platform which boasts high sensitivity and specificity in detecting CNS tumor cells.

https://uk.finance.yahoo.com/news/plus-therapeutics-secures-blue-shield-113000314.html

Centene Reports Strong Q1 Earnings, Raises Guidance

Centene reported strong Q1 earnings, with non-GAAP EPS of $3.37 surpassing expectations by $1.24 and revenue reaching $49.94 billion, a 7.1% year-over-year increase. The company also raised its 2026 premium and service revenue guidance by $1.0 billion to a range of $171.0 billion to $175.0 billion, and updated its 2026 GAAP diluted EPS guidance floor to greater than $2.37 and adjusted diluted EPS guidance floor to greater than $3.40. Analysts have reacted by modest price target increases, with Jefferies raising their target to $39 and BofA to $34, though both maintained their current ratings.

https://intellectia.ai/news/stock/centene-reports-strong-q1-earnings-raises-guidance

Earnings To Watch: Humana (HUM) Reports Q1 Results Tomorrow

Humana (NYSE:HUM) is set to report its Q1 earnings tomorrow, with expectations for 22.9% year-on-year revenue growth. The company reported a significant miss on full-year EPS guidance last quarter despite beating revenue expectations. Investors are showing positive sentiment in the health insurance sector, and Humana's stock performance ahead of earnings reflects this.

https://stockstory.org/us/stocks/nyse/hum/news/earnings/earnings-to-watch-humana-hum-reports-q1-results-tomorrow

A Look at Humana Inc (HUM) After 3.9% Gain -- GF Value $434.36 v

Humana Inc (HUM) shares rose 3.9% but are down over the past year. Despite recent gains, the stock is considered significantly undervalued by GuruFocus' GF Value, trading 48.5% below its intrinsic value estimate of $434.36. Insider buying activity suggests confidence in the company's future, though its P/E ratio is trading above its 5-year median, and its Valuation and Momentum scores are low.

https://www.gurufocus.com/news/8821079/a-look-at-humana-inc-hum-after-39-gain-gf-value-43436-vs-price-22362

Trending Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Packaging Corporation of America ($PKG) Stock Forecast: Up 3.1% Today

Humana Inc. Price History

26.01.2026 - HUM Stock was up 5.5%

• The positive partnership between Humana and data automation startup Veda to enhance provider directories has led to a bullish movement in Humana's stock today, aiming to address inaccuracies in provider information and improve patient care access.
• Despite a significant year-to-date stock price decline, analysts suggest that Humana’s current undervaluation may attract investors seeking discounted opportunities.
• Analysts point out three key factors that could drive Humana's potential upside: strong long-term revenue growth, economies of scale, and a strategic focus on Medicare Advantage plans, indicating consistent growth and capital efficiency.
• The upcoming resolution of Medicare Advantage payment rates may influence investor sentiment towards managed-care stocks like Humana, with a final announcement expected by April 6, following the after-hours slip in UnitedHealth (UNH) stock.

07.03.2026 - HUM Stock was up 11.4%

• Humana's bullish movement can be attributed to the decision by the Trump administration to significantly raise Medicare insurer payments, benefiting companies like Humana that offer Medicare Advantage plans.
• The finalized 2.48% rate increase for 2027 Medicare Advantage and Part D payments by CMS provided clarity and support for Humana's profitability in the Medicare Advantage sector.
• Investor attention towards healthcare companies like Humana has increased due to brighter prospects in the managed care industry following the rise in Medicare Advantage rates for 2027.
• The market movement reflects a positive sentiment towards health insurance stocks, with companies like Humana expected to benefit from the revised Medicare payment plans and increased profitability in the sector.

11.01.2026 - HUM Stock was down 7.6%

• Humana's wider fourth-quarter loss was primarily driven by increased medical costs and decreased quality ratings for its Medicare plans. This led to a less optimistic earnings outlook for 2026.
• Despite exceeding revenue forecasts, concerns about lower quality ratings on its Medicare Advantage plans and the potential loss of government bonus payments affected investor confidence, resulting in a bearish movement for Humana's stock.
• The contrast between the strong revenue performance and the negative earnings forecast for 2026 likely influenced the downward trend in Humana's stock, reflecting a more pessimistic market sentiment towards the company.

11.01.2026 - HUM Stock was down 5.7%

• Humana's ambitious growth strategy to become the largest Medicare Advantage insurer by 2026, despite facing challenges such as elevated medical spending and investor concerns, might have raised doubts among investors, leading to the bearish market movement.
• The wider fourth-quarter loss reported by Humana, driven by surging medical costs and downgraded quality ratings for its Medicare plans, likely contributed to the negative investor sentiment and the stock's decline.
• Despite exceeding revenue forecasts and narrowing its loss compared to the previous year, Humana's disappointing 2026 earnings guidance, falling significantly below analyst expectations, could have triggered the bearish market movement as investors reevaluated the company's future prospects.
• The market's reaction to Humana's performance highlights the importance of managing cost pressures, maintaining plan quality, and meeting investor expectations in the highly competitive healthcare insurance industry.

07.03.2026 - HUM Stock was up 8.8%

• Humana's stock surged 11% after a 2.48% rate increase for Medicare Advantage plans in 2027 was finalized by the Centers for Medicare and Medicaid Services (CMS), exceeding initial proposals. This favorable rate update removes uncertainty for investors and provides breathing room for the company to work towards its earnings targets.
• The decision to boost Medicare Advantage payments for 2027 not only positively impacted Humana but also other major healthcare companies like UnitedHealth and CVS Health, leading to a sector-wide rally.
• Despite facing challenges like margin pressure and integrating new members, Humana is well-positioned to benefit from the increased payments, which are projected to funnel over $13 billion in additional payments, providing a significant boost to the company's revenue outlook.
• This market movement reflects investor confidence in Humana's ability to navigate industry challenges and capitalize on the favorable regulatory environment to drive growth and profitability in the coming years.

24.01.2026 - HUM Stock was down 5.1%

• Humana's weaker Q4 2025 results and soft 2026 GAAP EPS outlook have led to a bearish market movement as investors digest the short-term earnings pressures and regulatory uncertainties.
• The company's decision to affirm its dividend despite these challenges signals a dedication to shareholder returns and financial stability, albeit in the face of profitability hurdles.
• Analysts and investors are likely reevaluating Humana's position in the healthcare sector, weighing the affirmed dividend against the backdrop of evolving regulatory risks and the company's strategic focus on medical cost control and value-based care.
• The broader market sentiment towards healthcare stocks, regulatory concerns, and the company's ability to navigate policy-driven risks are contributing factors to Humana's bearish movement today.

28.03.2026 - HUM Stock was up 5.2%

• Humana (HUM) experienced a strong bullish movement today, with shares rising by 3.9%.
• The positive market movement can be attributed to the overall positive sentiment in the health insurance sector, as investors anticipate the company's Q1 earnings report.
• Analysts and investors are showing confidence in Humana's future performance, as indicated by the significant undervaluation of the stock according to GuruFocus' GF Value estimate.
• The upcoming earnings report and expectations for strong revenue growth are likely driving the bullish momentum in Humana's stock price.

28.00.2026 - HUM Stock was down 9.2%

• Humana's stock experienced a significant 21.13% decline following the Centers for Medicare & Medicaid Services' unexpected announcement of a minimal 0.09% increase in Medicare Advantage payments for 2027.
• The lower-than-anticipated funding raised concerns about profit margins not only for Humana but also for other industry players like CVS Health and UnitedHealth Group.
• The soft outlook for fiscal year 2026, coupled with concerns over proposed payment rates and declining memberships in Medicare Advantage and Medicaid, contributed to investor unease and the bearish movement in Humana's stock.
• As Humana navigates these regulatory challenges and adjusts its cost structures, investors are eagerly awaiting the company's upcoming conference call to gain insights into its earnings performance and short-term outlook amidst the evolving healthcare landscape.

07.03.2026 - HUM Stock was up 5.8%

• Humana's stock surged by 9.8% in premarket trading, outperforming other companies like Valmont Industries and Loews.
• The bullish movement can be attributed to the overall positive sentiment in health insurance stocks, following the federal government's announcement of a 2.48% increase in Medicare payments to insurers for the next year.
• The decision to significantly raise Medicare payments for private health insurers, including Humana, reflects a favorable regulatory environment for the industry, leading to increased investor confidence and driving the stock price higher.
• Investors are reacting positively to the news, as the revised plan means additional revenue for companies like Humana through Medicare Advantage, a key component of their business, ultimately boosting the stock's performance.

10.01.2026 - HUM Stock was down 5.2%

• Humana stock reached a 52-week low at $185.98, marking a significant -27.98% decline over the last year attributed to industry-wide pressures and internal challenges.
• Guggenheim has maintained a Buy rating on Humana stock ahead of its 4Q25 earnings release, citing uncertainties related to guidance, growth in Medicare Advantage enrollment, and profitability.
• The introduction of Agent Assist, an artificial intelligence tool developed by Humana in collaboration with Google Cloud, is expected to improve customer service effectiveness gradually, prompting investors to consider long-term advantages over short-term gains.
• Despite obstacles and varying analyst opinions, the upcoming Q4 2025 earnings report of Humana, coupled with apprehensions regarding policy changes and Medicare Advantage payment rates, are influencing investor sentiment and contributing to the recent market downturn.

21.03.2026 - HUM Stock was up 5.1%

• Despite a Humana director reporting zero common shares, this development had little impact on the stock price.
• The rise in Humana's stock value was likely influenced by a positive market outlook following another healthcare company's strong Q1 2026 performance, which had a ripple effect on Humana and similar firms.
• Approval of key proposals during Humana's annual meeting, including director re-election and stock incentive plan approval, likely boosted investor confidence in the company's future.
• Factors such as disclosed lobbying expenditures on critical healthcare issues, favorable analyst evaluations, and price targets likely contributed to the upward momentum in Humana's stock value.

21.03.2026 - HUM Stock was up 6.8%

• Today, Humana experienced a significant bullish movement, which may be attributed to the outcomes of their annual shareholder meeting. During the meeting, all ten directors were re-elected, the 2026 auditor ratification was approved, and the stock incentive plan was adopted. These decisions indicate strong investor confidence in the company's leadership and strategic direction.
• The rejection of the proposal to tighten oversight on golden parachute arrangements could have also contributed to the positive market sentiment, suggesting support for the company's executive compensation practices.
• The disclosure of lobbying expenses related to key healthcare issues such as Medicare Advantage and Medicaid, coupled with favorable ratings and price targets from Wall Street analysts, likely boosted investor confidence in Humana's future prospects.
• In summary, the combination of favorable shareholder decisions, strategic efforts like the expansion of palliative care services, and positive analyst sentiment may have driven the bullish momentum in Humana's stock today.